Several studies have demonstrated a relationship between rodent body weight and tumor incidence for some tissue/organ sites. It is not uncommon for a chemical tested for carcinogenicity to also affect body weight. In such cases, comparisons of tumor incidence may be biased by body-weight differences across dose groups. A simple procedure was investigated for reducing this bias. This procedure divides the animals into a few groups based on body weight. Body weight at 12 months was used, before the appearance of a tumor was likely to affect body weight. Statistics for dose-response trend tests are calculated within body weight strata and pooled to obtain an overall dose-response trend test. This procedure is analogous to that currently used, of stratifying animals, based on their age at the time of removal from a study. Age stratification is used to account for differences in animal age across dose groups, which can affect comparisons of tumor incidence. Several examples were investigated where the high-dose group had reduced body weights and associated reductions in tumor incidence. When the data were analyzed by body-weight strata, some positive dose-response trends for tumor incidence were demonstrated. In one case, the weight-adjusted analysis indicated that a negative dose-response trend in tumor incidence was a real effect, in addition to a body weight reduction. These examples indicate that it is important to consider the effects of body weight changes as low as 10%, and perhaps below, that were caused by chemicals in 2-year bioassays for carcinogenesis. The simple procedure of analyzing tumor incidence within bodyweight strata can reduce the bias introduced by weight differences across dose groups.
Numerous studies have shown a positive correlation between rodent body weight and tumor incidence for some tissue sites (Kari and Abdo, 1995; Tannenbaum, 1940; Turturro et al., 1993) . This suggests that adjustments of tumor rates should be made when animal body weights differ across dose groups. When toxicity or reduced food consumption results in lowered body weights as the dose increases, this could artificially result in a finding of reduced tumor incidence with reduced dose. On the other hand, chemicals with therapeutic and/or nutritional components may result in higher body weights with increasing dose, which could artificially inflate tumor rates. Hart and Turturro (1997) provide an overview of dietary intake, body weight, and tumor incidence. Suggested potential mechanisms for the inhibition of cancer include decreases in cellular proliferation and increases in apoptosis in some organs affected by decreased body size. Decreases in body weight serve as a surrogate for decreases in caloric intake that lead to reduced DNA damage with reduced body temperature, decreased oxidative damage, and increased DNA repair. Seilkop (1995) uses historical control animal data to provide a relationship between tumor incidence and body weight upon which tumor rate adjustments are based. This provides a procedure when historical data are available, and the tumorincidence relationship to body weight for the current chemical under test follows historical trends. The procedure suggested in this paper divides the experimental data into body weight groups from the current bioassay and calculates dose-response statistics within groups. An overall test for a dose-response trend is computed by pooling the statistics across weight groups in the same manner as age adjusted analyses are currently calculated. The weight adjustment approach is illustrated for 3 chemicals, in which lower body weights in the high dose group may be associated with lower tumor incidence.
TREND TEST ADJUSTED FOR BODY WEIGHT
It has been recognized for several decades that tumor rates increase dramatically with age. Differences in survival across dose groups in a chronic bioassay can affect tumor rates and bias dose-response trend tests. Life table tests avoid this bias by considering the number of animals at risk (survivors) for fatal tumors, at a series of time points. For incidental (nonfatal) tumors, the data are stratified based on time on study, i.e., age of animals, in order to minimize differential survival biases. Dose-response trend statistics are calculated within age groups and then pooled for an overall test. These procedures are described by Peto et al. (1980) and are used widely. In the The opinions expressed in this manuscript are solely those of the authors and not necessarily those of the U.S. Food and Drug Administration.
1 To whom correspondence should be addressed at National Center for Toxicological Research, 3900 NCTR Road, Jefferson, AR 72079. Fax: 870 -543-7576. E-mail: dgaylor@nctr.fda.gov. absence of information on the cause of death, analyses frequently are conducted assuming that all tumors observed in dead and moribund animals are incidental, and a second (life  table) analysis is conducted assuming all tumors are the reason for death or the moribund condition. Obviously, all tumors in the terminal sacrifice group are incidentally observed.
The procedure to account for differences in body weight across dose groups that might influence tumor rates is a simple extension of the age adjustment procedure. In addition to the data being divided into age groups for incidental tumors, they are further divided into body weight groups. For incidental tumors, test statistics are calculated for each age-weight group and then pooled for overall tests. For fatal tumors, life table analyses account for age differences, and test statistics are calculated within each weight group and pooled for overall tests.
The test for a dose-response trend in the i th age-weight group is based on the statistic:
where D ij is the j th dose level for the i th age-weight group, O ij is the observed number of animals with a tumor at dose D ij in the i th age-weight group, and E ij is the expected number of animals with a tumor at dose D ij in the i th age-weight group under the null hypothesis of no-dose-response trend. That is, E ij is the tumor incidence over all dose groups multiplied by the number of animals, N ij , in the age-weight-dose group. The summation for the test statistic is over all the j dose levels. If a chemical has no effect on carcinogenicity, T i has an expected value of zero. The test for a dose-response trend is calculated by the approximate standard normal deviate
V i is the variance of T i and N i denotes the total number of animals, with and without tumors, in all the dose groups combined for the i th age-weight group. The overall test for a dose-response trend is given by
The advantage of combining test statistics is that individually weak trends for age-weight groups may combine to form a clear pattern. In the special case of comparing a single dose group with the controls, the calculations are simplified somewhat. Since D ij ϭ 0 for the controls, and D ij for the dosed group cancels out of the calculation for Z i , D ij can be set equal to one.
In older animals, the body weight might be influenced by the presence of disease, particularly a growing tumor, rather than the occurrence of a tumor influenced by the body weight. Seilkop (1995) investigated body weights at different ages and used the body weight of the animals after one year on study for adjustments. Turturro et al. (1993) show that body weights earlier than 12 months may have a higher correlation with tumor incidence at some tissue sites. For purposes of illustration, 12-month body weights are used here. For a given chemical the animals are divided into 3 weight groups; the lightest, middle, and heaviest thirds. For incidental tumors, the dead and moribund animals are divided into 3 age groups: those animals removed before 640 days (21 months) on study, animals removed between 640 days and the terminal sacrifice, and the animals removed at the terminal sacrifice of 24 months. This results in: 3 age groups ϫ 3 weight groups ϭ 9 age-weight groups.
EXAMPLES p-Nitrobenzoic Acid
In the first example, data from the National Toxicology Program (1994) two-year bioassay from p-nitrobenzoic acid are used to illustrate the weight stratification process for doseresponse tests for carcinogenicity. In this study the average body weights for female rats at 12 months were 271 g, 269 g, 260 g, and 243 g in the 0, 1250, 2500, and 5000 ppm dietary groups, respectively. The high-dose group weighed just 10% less than the control group. Seilkop (1995) and Turturro et al. (1993) indicate that mammary tumor incidence in female Fischer 344 rats is correlated with 12-month body weight. Hence, a weight-adjusted, dose-response analysis was conducted for mammary fibroadenoma, which has a high background incidence of 44% and for mammary carcinoma which has a low to moderate background rate of 4%.
The animals were divided into 3 weight groups: less than 250 g, 250 -269 g, and Ն 270 g at 12 months on study. This provided some animals in each dose group for each of the weight groups. As stated earlier, age groups for incidental tumors were selected for: less than 640 days (21 months) on study, 640 days up to terminal sacrifice, and 24-month terminal sacrifice.
The dose-response T i and V i scores for mammary fibroadenomas for the individual age-weight groups, considering all tumors as incidental, are shown in Table 1 . The calculation of T i and V i for the animals weighing less than 250 g at 12 months and dying before day 640 is now given. The incidences of mammary fibroadenoma were 1/3, 1/2, and 3/11 in the 1250-, 2500-, and 5000-ppm dose groups, respectively. No animals in this age-weight group were present in the controls. This is the only age-weight category that did not have animals in every dose group in the entire study. In this age-weight group the total incidence of fibroadenoma was 5/16. Under the null hypothesis of no-dose-response trend, the probability that an animal has a mammary fibroadenoma is 5/16, or 0.3125. The expected number of tumors in a dose group is the number of animals in the dose group times the overall tumor incidence in the age-weight group of 0.3125. Without loss of generality, the dose levels can be scaled to 0, 1, 2, and 4 for 0, 1250, 2500, and 5000 ppm, respectively (Table 2) .
There is a negative dose-response trend in this age-weight group as indicated by the negative value of T 1 . The values of T i and V i for the other age-weight groups are displayed in Table 1 . The overall dose-response trend test, considering all mammary fibroadenomas as observed incidentally at the time of removal of animals from the study, is obtained by combining the age-weight group scores from If the mammary fibroadenomas caused the removal of the animals from the study because of death or a moribund condition, then the life table analysis is more appropriate than the incidental tumor analysis. Incidence rates are based on the number of surviving animals of any age that were at risk at the time of observance of each tumor. The dose-response trend-test scores, T i and V i, are calculated for each body weight group and combined for an overall trend test. For example, in those animals with 12-month body weights below 250 g, the first mammary fibroadenoma occurred in the 2500-ppm dose group at 379 days. At that time, the number of animals at risk (number of survivors) in each dose group were 5, 5, 9, and 38 in the 0-, 1250-, 2500-, and 5000-ppm dose groups, respectively. Under the null hypothesis of no-dose-response trend, each of the (5 ϩ 5 ϩ 9 ϩ 38) 57 animals at risk had an equal chance of 1/57, or 0.0175, of developing the mammary fibroadenoma. The expected number of fibroadenomas for each dose group is the number of animals at risk in the dose group multiplied by 0.0175. The T i and V i scores for the first tumor are based on the data shown in Table 3 .
T i and V i scores are obtained in a similar manner at the time of each subsequent mammary fibroadenoma for the the animals weighing less than 250 g. Similar calculations are performed for the other 2 weight groups. The total T i and V i scores, considering that all dead and moribund animals with mammary fibroadenomas were removed from the study for that reason, are shown in The complete results of dose-response trend tests and comparisons of tumor rates in controls and the high dose group (5000 ppm), stratified by age and body weight for mammary fibroadenoma, and carcinoma are given in Table 5 . For comparison purposes, the results for which no adjustment for differences in body weight was made are also given.
O-Nitroanisole
The weight-adjusted dose-response trend test was applied to results obtained in a National Toxicology Program (1993) study for hepatocellular adenoma or carcinoma in female B6C3F1 mice administered o-nitroanisole at 0, 666, 2000, and 6000 ppm. The incidences of hepatocellular tumors were 1/9, 7/20, 10/13, and 1/3 at 0, 666, 2000, and 6000 ppm, respectively. When we considered that all hepatocellular tumors had been incidentally observed at the time animals were removed as dead or moribund, there was no evidence of a dose-response trend, whether or not analyses were conducted within weight groups.
When hepatocellular tumors were considered fatal, the life table analysis ignoring body weights showed a negative doseresponse trend with a statistical significance level of p Ͻ 0.10 N (NTP, 1993). However, a life table analysis stratified by body weights showed a strong positive dose-response trend. This can be observed from an examination of tumor incidence vs. dose within body weight groups (Table 6 ). The reason for the negative dose-response for the life-table analysis, ignoring body weight, is that the only dead and moribund animals in the highest dose group (6000 ppm) had low body weights, which are associated with lower hepatocellular tumor incidence. The values for T i and V i for the weight-adjusted life-table analysis for fatal hepatocellular tumors are given in Table 7 . The overall life-table-trend test, adjusted for body weight, is Z ϭ15.12ր ͱ25.6354 ϭ 2.99 which has a statistical significance of p Ͻ 0.003. Hence, the false impression of a negative dose-response for hepatocellular tumor administered o-nitroanisole apparently was due to depressed body weights in the higher dose group of 44, 43, 38, and 25 g at 0, 666, 2000, and 6000 ppm, respectively. The weight-adjusted dose-response trend test shows a highly significant increase (positive trend) with administration of o-nitroanisole. 
Doxylamine Succinate
Jackson and Blackwell (1993) present the results of a 2-year carcinogenicity study, conducted at the National Center for Toxicological Research, in which Fischer 344 rats were administered 0, 500, 1000, and 2000 ppm of doxylamine succinate in the diet. The average body weight for females after 12 months on the study were 295, 282, 263, and 229 g in the 0-, 500-, 1000-, and 2000-ppm groups, respectively. The results of the dose-response trend tests are summarized in Table 8 . Ignoring the decreases in body weight with higher doses, results show significant negative dose-response trends for mammary tumors. The animals were divided into 3 groups on the basis of 12-month body weights: Յ254 g, 255-284 g, and Ն285 g. Even for the dose-response trend tests, adjusted for body weight, the negative trend remains. It appears that doxylamine succinate causes a decrease in mammary tumors by another mechanism, in addition to a reduction in body weight.
DISCUSSION
Several studies have shown a positive correlation between rodent body weight and tumor incidence for some tissue sites. This indicates that weight-adjusted comparisons of tumor rates are needed when animal body weights differ across dose groups. A standard covariance analysis of tumor incidence and body weight is not appropriate because the treatment (chemical) also causes the difference in body weights. Seilkop (1995) uses historical tumor rates from control animals to provide a relationship between tumor incidence and body weight upon which tumor-rate adjustments are made. This requires that the current study follow historical norms, if they are available.
The procedure proposed in this paper divides the animals into body weight groups and calculates dose-response trend statistics within these groups. An overall test for a doseresponse trend is calculated by pooling the test statistics across body weight groups in the same manner as age-adjusted analyses are currently calculated. Hence, no external data to the particular bioassay, or additional assumptions, are required. The dose-response trend tests used in this paper follow the procedures of Peto et al. (1980) . However, body weight stratification can be used for any statistical dose-response test.
The proposed test for trend pools results on the basis of equal statistical weight for each age-weight group, as is the case for commonly used age-adjusted tests. Perhaps a better procedure might be to weight the T i inversely by their variances. It is beyond the scope of this introductory paper to examine this issue. Perhaps this should be a subject for future research.
When a chemical causes an increase in body weight and a subsequent increase in tumor incidence, the analysis stratified by body weight will tend to decrease a positive dose-response trend, and hence decrease its statistical significance, if any. When a chemical causes a decrease in body weight and a subsequent decrease in tumor incidence, the analysis within body weight groups will tend to increase the dose-response trend. For example, without an adjustment for differing body weights across dose groups, p-nitrobenzoic acid did not exhibit a dose-response trend for mammary fibroadenoma or carcinoma. When adjusted for body weight, mammary carcinoma showed a stronger indication of an effect from p-nitrobenzoic acid, but still not statistically significant. However, when mammary fibroadenomas were sorted into body weight groups, there was statistical evidence of an effect of p-nitrobenzoic acid (Table 5) . Seilkop (1995) also found increases in mammary tumors when compared to historical controls with the same 12-month body weights.
For female B6C3F1 mice administered o-nitroanisole, the decrease in body weight at the high dose and accompanying low incidence of hepatocellular tumors resulted in a no-doseresponse trend. However, when the data were analyzed by weight groups, a highly significant dose-response trend was noted. Seilkop (1995) also found increases in the incidence of liver tumors when compared to historical controls with the same average 12-month body weights.
For doxylamine succinate administered to female Fischer 344 rats, the negative dose-response trend for mammary tumors remained, even after the weight-adjusted analysis. This indicates that doxylamine succinate may have a beneficial effect for mammary tumors, in addition to the effect from body weight reduction. Ames and Gold (1990) suggest that lower body weight may indicate cytotoxicity, which could cause compensatory cell proliferation providing increased opportunities for mutations, and as a result artificially inflate tumor incidence at high doses. Analysis of tumor incidence results by body weight strata should adjust for such a negative association between tumor incidence and body weight. This paper does not address the issue of when it is necessary to account for differences in body weight across dose groups. In the example with p-nitrobenzoic acid, substantial effects on dose-response trend tests were obtained with a 10% difference in body weights. Seilkop (1995) and Turturro et al. (1993) show effects on tumor incidence for body weight differences less than 10%. Since stratifying by body weight is a simple procedure that imposes no additional assumptions, it could be applied universally. Nothing is lost in those cases where body weight has no influence, other than some additional computational time.
Much of the data indicating a relationship between body weight and tumor incidence come from caloric restriction studies. Suggested mechanisms for influencing tumor incidence appear to be related to caloric intake rather than body weight (Hart and Turturro, 1997) . Body weight serves as a simple, direct surrogate for dietary intake. It might be of interest for future research to investigate whether stratifying on dietary intake and body weight provide similar results. This paper does not address the issue of the optimum number of age-weight groups. Currently, analyses generally divide the data for a bioassay into a few (3 or 4) age groups. Similarly, in the examples here, the body weights are divided into 3 groups. The use of 3 age groups and 3 weight groups resulted in 9 age-weight groups. Hence, some groups contained a small number of animals. The advisability of using more weight groups could be the subject of additional research.
Perhaps corrections of tumor incidence for body-weight changes should not be made. It can be argued that this is part of the mechanism through which a chemical influences tumor rates, and it should contribute accordingly to the risk. Adjustments are not made for differences across doses of other secondary mechanisms that influence tumor rates, such as cell proliferation and cell-death rates. On the other hand, it could be argued that these secondary mechanisms at low doses may not differ from unexposed control levels, and therefore, tumor rates should be adjusted for their effects. The adjusted trend test proposed here to accommodate differences in body weight across dose groups is similar to adjusted trend tests commonly in use to accommodate differences in non-cancer mortality across dose groups.
The above examples indicate that it is important to consider the effects of body weight changes caused by chemicals in 2-year bioassays for carcinogenesis. Such effects can be significant, even in studies where average body weight differences are 10% or perhaps less. The simple procedure of dividing the animals into a few groups stratified by body weight (12-month body weight was used in these analyses), and calculating dose-response-trend statistics within body weight groups, provides an easy method to adjust for body-weight differences across dose groups.
